Baxter International Inc (NYSE:BAX) SVP Scott Pleau sold 10,686 shares of the firm’s stock in a transaction that occurred on Tuesday, July 10th. The shares were sold at an average price of $75.00, for a total transaction of $801,450.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Scott Pleau also recently made the following trade(s):
- On Monday, June 25th, Scott Pleau sold 27,197 shares of Baxter International stock. The shares were sold at an average price of $73.57, for a total transaction of $2,000,883.29.
NYSE:BAX traded up $0.46 on Thursday, reaching $74.78. 1,769,714 shares of the stock traded hands, compared to its average volume of 3,086,701. The company has a market capitalization of $39.96 billion, a PE ratio of 30.10, a P/E/G ratio of 1.93 and a beta of 0.81. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.63. Baxter International Inc has a 1-year low of $58.81 and a 1-year high of $75.62.
Baxter International (NYSE:BAX) last released its earnings results on Thursday, April 26th. The medical instruments supplier reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.08. The business had revenue of $2.68 billion during the quarter, compared to the consensus estimate of $2.62 billion. Baxter International had a net margin of 7.75% and a return on equity of 15.70%. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.58 EPS. research analysts predict that Baxter International Inc will post 2.89 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, July 2nd. Stockholders of record on Friday, June 1st were given a dividend of $0.19 per share. This is an increase from Baxter International’s previous quarterly dividend of $0.16. The ex-dividend date was Thursday, May 31st. This represents a $0.76 annualized dividend and a dividend yield of 1.02%. Baxter International’s dividend payout ratio (DPR) is 30.65%.
Hedge funds have recently made changes to their positions in the company. Robecosam AG acquired a new stake in shares of Baxter International during the 4th quarter worth approximately $103,000. Vigilant Capital Management LLC acquired a new stake in shares of Baxter International during the 2nd quarter worth approximately $131,000. Ostrum Asset Management acquired a new stake in shares of Baxter International during the 1st quarter worth approximately $121,000. IHT Wealth Management LLC grew its position in shares of Baxter International by 71.9% during the 1st quarter. IHT Wealth Management LLC now owns 2,462 shares of the medical instruments supplier’s stock worth $156,000 after buying an additional 1,030 shares during the period. Finally, Bruderman Asset Management LLC acquired a new stake in Baxter International in the 1st quarter valued at $168,000. 83.44% of the stock is owned by institutional investors.
A number of brokerages recently issued reports on BAX. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $81.00 price objective for the company in a report on Monday, May 28th. Bank of America raised their price objective on shares of Baxter International from $73.00 to $83.00 and gave the company a “buy” rating in a report on Tuesday, May 22nd. Piper Jaffray Companies reiterated an “overweight” rating and issued a $77.00 price objective on shares of Baxter International in a report on Thursday, May 31st. Citigroup raised their price objective on shares of Baxter International from $70.00 to $72.00 and gave the company a “neutral” rating in a report on Monday, April 30th. Finally, Stifel Nicolaus raised their price objective on shares of Baxter International from $71.00 to $72.00 and gave the company a “hold” rating in a report on Monday, April 30th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Baxter International currently has a consensus rating of “Buy” and an average price target of $73.25.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.